Codexis discovers, develops and sells proteins to its clients. The company has two segments: Performance Enzymes, which uses its technology to develop enzymes for customers using next generation sequencing and polymerase chain reaction for in vitro molecular diagnostic and molecular biology research applications; and Novel Biotherapeutics, in which it has announced a global development, option and license agreement with Societe des Produits Nestle S.A. to develop CDX-6114, its own orally administrable enzyme therapeutic candidate for the potential treatment of phenylketonuria. The company's products include protein catalysts, chemical intermediates and Codex? biocatalyst panels and kits.
  • TickerCDXS
  • ISINUS1920051067
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Macro Vision: Sector Synopsis

Investors continue to prefer the stability of the U.S. relative to emerging markets. The decline in emerging markets and their currencies suggest global risk aversion. U.S. equity markets are, by contrast, not showing any significant signs of coming unhinged as a result of this rout in emerging markets. We continue to monitor the following to assess the health of the U.S. market: • U.S. Dollar: The U.S. dollar remains the de-facto world currency and has aided the U.S. equity markets in staying a step above the malaise in global markets. However we would prefer to see stabilization in eme...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Macro Vision: U.S. Equity Strategy

The last several months have been that of digestion and consolidation. While Sector and group leadership have taken a back seat to stock selection, rotations still seem to be the norm. We have on a number of occasions indicated that the current rotations are reminiscent of the rotations of 1994. Bill Clinton was President and in that year the Republicans had swept the house under their “Contract with America”. Clinton had imposed tariffs on steel imports late in 1993 and with the onslaught of foreign competition, the administration also pushed for punitive tariffs on Japanese autos and ...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

MarketLine Department

Mascoma Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Mascoma Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Mascoma Corporation since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage....

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior